News

Weight loss drugs like semaglutide could add £4.5 billion to the UK economy annually, boosting productivity and reducing ...
European governments are examining whether US President Donald Trump can force them to pay more for prescription medicines, ...
Novo Nordisk is doubling down on its oral drug strategy for obesity with a new partnership worth up to $2.2bn with Septerna.
EToro climbed as much as 42% in its first session as a public company, following a nearly $620 million upsized IPO. The ...
Novo Nordisk looks to harness Septerna’s broader GPCR drug pathways, which include GLP-1, for obesity and diabetes treatments ...
Indianapolis-based Eli Lilly & Co. announced promising results from a large study of its own tablet in diabetes patients last ...
The Ozempic maker and its peers are setting their sights on oral obesity medications to diversify their portfolios and remain ...
Individualized ocular characteristics should be considered before starting GLP-1 RA therapies for weight loss and diabetes ...
Novo Nordisk A/S is partnering with US biotech Septerna Inc. on the development of oral pills for obesity in a deal ...
Weekly jabs might not sound glamorous, but Mounjaro and Ozempic are making headlines for more than just managing blood sugar.
Shoppers in the United States have been worried about the impact tariffs might have on their groceries and cost of living, but finally there is a bit of good news—thanks to a new executive order ...
Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...